Our Policies on Ethics
As we work to develop new medicines, our strict standards of moral and ethical conduct are guided by the help and oversight of institutional review boards, regulatory authorities, and industry association guidelines governing ethical clinical trial conduct and research integrity. Additionally, we have created our own agency to oversee our research ethics and integrity.
All Pfizer-sponsored interventional studies are conducted in accordance with applicable laws and regulations, as well as principles derived from relevant international standards including:
The Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines
The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6 guideline for Good Clinical Practice
PhRMA’s Principles on Conduct of Clinical Trials and Communication of Clinical Trial Results
The Declaration of Helsinki
The United States Belmont report
We strive to maintain the highest ethical, scientific, and clinical standards in all our clinical research around the world. We regularly review our policies to align them with Pfizer's vision, values, and goals, and with our stakeholders' evolving priorities.
Related Articles
Programs & Initiatives
Bridging the Gap: Community-Based Organizations Seek Trust, Tools and Funding to Advance Public Health
Community-based organizations (CBOs) are the cornerstone of community health—yet across the country they face substantial uncertainty, according to a new national survey supported by the Pfizer Multicultural Health Equity Collective (The Collective).
Science & Innovation
Pursuing the Next Breakthrough in Cancer Cachexia
Cachexia, a complex wasting syndrome, impacts an estimated 9 million people worldwide. Currently, there are no FDA-approved treatments targeting its underlying cause.
Science & Innovation
Brighter Together: How the Pharmaceutical Industry is Shining a Light on a Rare Cause of Heart Failure
Among the lesser known causes of heart failure is transthyretin amyloid cardiomyopathy (ATTR-CM). Early suspicion and diagnosis are crucial. That’s why Pfizer is working with other industry partners as part of the ASPIRE group, led by Amyloidosis Research Consortium (ARC), to accelerate earlier detection and diagnosis.
Clinical Trial Resources
Learn more about the process of joining a clinical trial and find a trial near you.
Clinical Trials
We proudly partner with thousands of study sites and tens of thousands of trial participants around the world. It’s these clinical trials that lead to life-changing medicines.
Go to Pfizer Clinical Trials Site Details